{
    "clinical_study": {
        "@rank": "104124", 
        "acronym": "APPEAL-Taiwan", 
        "arm_group": {
            "arm_group_label": "Pts with POAG or OH", 
            "description": "Patients with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan\u00ae 0.01%)."
        }, 
        "brief_summary": {
            "textblock": "This is a study of bimatoprost 0.01% (LUMIGAN\u00ae 0.01%) in subjects with primary open-angle\n      glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated\n      intraocular pressure (IOP)."
        }, 
        "brief_title": "A Study of Bimatoprost 0.01% in the Clinical Setting", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glaucoma, Primary Open Angle", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Hypertension", 
                "Ocular Hypertension", 
                "Glaucoma, Open-Angle"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of primary open-angle glaucoma or ocular hypertension\n\n          -  Determined by the treating physician to require treatment with bimatoprost 0.01%.\n\n        Exclusion Criteria:\n\n          -  Previous use of Lumigan\u00ae 0.01%"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects with primary open-angle glaucoma or ocular hypertension"
            }
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814761", 
            "org_study_id": "GMA-AP-EYE-AGN-001"
        }, 
        "intervention": {
            "arm_group_label": "Pts with POAG or OH", 
            "description": "One drop of bimatoprost 0.01% (Lumigan\u00ae 0.01%) in the affected eye(s) every evening for 12 weeks.", 
            "intervention_name": "Bimatoprost 0.01%", 
            "intervention_type": "Drug", 
            "other_name": "Lumigan\u00ae 0.01%"
        }, 
        "intervention_browse": {
            "mesh_term": "Bimatoprost"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 31, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Taichung City", 
                    "country": "Taiwan"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Center for Drug Evaluation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of Patients With Ocular Hyperemia", 
            "safety_issue": "No", 
            "time_frame": "12 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814761"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Intraocular Pressure (IOP)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "measure": "Percentage of Patients Who Discontinue Due to an Adverse Event", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}